No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.
Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.
Plachouras
D
D
Fourth Department of Internal Medicine, Attiko University General Hospital, Haidari, Greece. dplach@med.uoa.gr
Giannitsioti
E
E
Athanassia
S
S
Kontopidou
F
F
Papadopoulos
A
A
Kanellakopoulou
K
K
Giamarellou
H
H
D000081:Acetamides / Q000009:adverse effects*; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015994:Incidence; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects*; D011736:Pyridoxine / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid; D011736:Pyridoxine